Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
NCT ID: NCT02323880
Last Updated: 2025-01-14
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
59 participants
Study Classification
INTERVENTIONAL
Study Start Date
2015-10-30
Study Completion Date
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This phase I trial studies the side effects and best dose of selinexor in treating younger patients with solid tumors or central nervous system (CNS) tumors that have come back (recurrent) or do not respond to treatment (refractory). Drugs used in chemotherapy, such as selinexor, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
NCT01158300
Brain and Central Nervous System Tumors
COMPLETED
PHASE1
Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours
NCT03326388
Neurofibromatosis Type 1
Plexiform Neurofibroma
Optic Nerve Glioma
COMPLETED
PHASE1/PHASE2
Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
NCT02808650
Childhood Solid Neoplasm
Recurrent Malignant Solid Neoplasm
Recurrent Primary Central Nervous System Neoplasm
+2 more
COMPLETED
PHASE1
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
NCT00091182
Childhood Central Nervous System Germ Cell Tumor
Childhood Extragonadal Germ Cell Tumor
Childhood Hepatoblastoma
+23 more
COMPLETED
PHASE2
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
NCT02780804
Brain Stem Neoplasm
Pineal Region Neoplasm
Recurrent Lymphoma
+7 more
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PRIMARY OBJECTIVES:
I. To determine the recommended phase 2 dose (RP2D) or the maximum tolerated dose (MTD) of the tablet formulation of selinexor in children with recurrent/refractory solid and CNS tumors.
II. To describe the toxicities of selinexor in children with recurrent/refractory solid and CNS tumors.
III. To characterize the pharmacokinetics of the tablet formulation of selinexor in children with recurrent/refractory solid and CNS tumors.
SECONDARY OBJECTIVES:
I. To determine the antitumor effect of selinexor in a preliminary manner in children with recurrent/refractory solid and CNS tumors.
II. To determine the pharmacodynamic properties of selinexor in children and adolescents with refractory solid tumors in plasma proteins and whole blood ribonucleic acid (RNA).
III. To explore the penetration, pharmacodynamic effects, and biologic effects of selinexor in tumor tissue of patients with recurrent/refractory high-grade gliomas (HGG) requiring resection.
IV. To further assess the toxicity and antitumor effects of selinexor in children with recurrent/refractory HGG in expanded cohorts following dose-escalation by measuring rate of objective radiographic response (medical patients) and rate of progression-free survival (PFS) six months from the start of treatment (surgical patients).
OUTLINE: This is a dose escalation study.
Patients receive selinexor orally (PO) on either a twice weekly (days 1, 3, 8, 10, 15, 17) or once weekly (days 1, 8, 15, and 22) schedule. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 30 days.
I. To determine the recommended phase 2 dose (RP2D) or the maximum tolerated dose (MTD) of the tablet formulation of selinexor in children with recurrent/refractory solid and CNS tumors.
II. To describe the toxicities of selinexor in children with recurrent/refractory solid and CNS tumors.
III. To characterize the pharmacokinetics of the tablet formulation of selinexor in children with recurrent/refractory solid and CNS tumors.
SECONDARY OBJECTIVES:
I. To determine the antitumor effect of selinexor in a preliminary manner in children with recurrent/refractory solid and CNS tumors.
II. To determine the pharmacodynamic properties of selinexor in children and adolescents with refractory solid tumors in plasma proteins and whole blood ribonucleic acid (RNA).
III. To explore the penetration, pharmacodynamic effects, and biologic effects of selinexor in tumor tissue of patients with recurrent/refractory high-grade gliomas (HGG) requiring resection.
IV. To further assess the toxicity and antitumor effects of selinexor in children with recurrent/refractory HGG in expanded cohorts following dose-escalation by measuring rate of objective radiographic response (medical patients) and rate of progression-free survival (PFS) six months from the start of treatment (surgical patients).
OUTLINE: This is a dose escalation study.
Patients receive selinexor orally (PO) on either a twice weekly (days 1, 3, 8, 10, 15, 17) or once weekly (days 1, 8, 15, and 22) schedule. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 30 days.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Malignant Glioma
Recurrent Brain Neoplasm
Recurrent Childhood Central Nervous System Neoplasm
Recurrent Childhood Glioblastoma
Recurrent Lymphoma
Recurrent Malignant Solid Neoplasm
Refractory Lymphoma
Refractory Malignant Solid Neoplasm
Refractory Primary Central Nervous System Neoplasm
WHO Grade 3 Glioma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (selinexor)
Patients receive selinexor PO on either a twice weekly (days 1, 3, 8, 10, 15, 17) or once weekly (days 1, 8, 15, and 22) schedule. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
Group Type
EXPERIMENTAL
Pharmacological Study
Intervention Type
OTHER
Correlative studies
Selinexor
Intervention Type
DRUG
Given PO
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pharmacological Study
Correlative studies
Intervention Type
OTHER
Selinexor
Given PO
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
ATG-010
CRM1 Nuclear Export Inhibitor KPT-330
KPT 330
KPT-330
KPT330
Nexpovio
Selective Inhibitor of Nuclear Export KPT-330
SINE KPT-330
Xpovio
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must have a body surface area (BSA) \>= 0.84 m\^2
* Diagnosis:
* Part A: Patients with recurrent or refractory solid tumors, including lymphoma and CNS tumors, are eligible; patients must have had histologic verification of malignancy at original diagnosis or relapse except in patients with intrinsic brain stem tumors, optic pathway gliomas, or patients with pineal tumors and elevations of cerebrospinal fluid (CSF) or serum tumor markers including alpha-fetoprotein or beta-human chorionic gonadotropin (HCG)
* Part B: Patients with recurrent or refractory high grade glioma (World Health Organization \[WHO\] grade III/IV) including disseminated tumors (excluding diffuse intrinsic pontine glioma \[DIPG\]), not requiring surgical resection; patients must have had histologic verification of malignancy at original diagnosis or relapse
* Part C: Patients with recurrent or refractory high grade glioma (WHO grade III/IV) and requiring surgical resection (excluding DIPG and disseminated tumors), who in the opinion of treating physicians, are medically stable to receive 2 doses of selinexor (8-10 days of treatment) before undergoing surgery without compromising the success of the procedure; note that if, in the opinion of treating physicians, current symptoms necessitate surgery before 2 doses will be able to be received, surgery should not be delayed to administer selinexor, and the patient would be ineligible for protocol therapy
* Disease status:
* Part A: Patients must have either measurable or evaluable disease
* Parts B and C: Patients must have measurable disease on imaging
* Patient's current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life
* Karnofsky \>= 50% for patients \> 16 years of age and Lansky \>= 50 for patients =\< 16 years of age; Note: Neurologic deficits in patients with CNS tumors must have been relatively stable for at least 7 days prior to study enrollment; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
* Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment; if after the required timeframe, the numerical eligibility criteria are met, e.g. blood count criteria, the patient is considered to have recovered adequately
* Myelosuppressive chemotherapy: At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea)
* Hematopoietic growth factors: At least 14 days after the last dose of a long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth factor; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair
* Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair
* Immunotherapy: At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines
* Antibodies: \>= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =\< 1
* Corticosteroids: If used to modify immune adverse events related to prior therapy, \>= 14 days must have elapsed since last dose of corticosteroid
* External beam radiation therapy (XRT): At least 14 days after local palliative XRT (small port); at least 150 days must have elapsed if prior total body irradiation (TBI), craniospinal XRT or if \>= 50% radiation of pelvis; at least 42 days must have elapsed if other substantial bone marrow (BM) radiation
* Stem cell infusion without TBI: No evidence of active graft vs. host disease and at least 56 days must have elapsed after transplant or stem cell infusion
* Patients must not have received prior exposure to selinexor
* For patients with solid tumors without known bone marrow involvement:
* \* Peripheral absolute neutrophil count (ANC) \>= 1000/mm\^3
* \* Platelet count \>= 100,000/mm\^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
* \* Hemoglobin \>= 8.0 g/dL at baseline (may receive red blood cell \[RBC\] transfusions)
* Patients with known bone marrow metastatic disease will be eligible for study if they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity; at least 5 of every cohort of 6 patients must be evaluable for hematologic toxicity for the dose-escalation part of the study; if dose-limiting hematologic toxicity is observed, all subsequent patients enrolled on Part A must be evaluable for hematologic toxicity
* Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70 ml/min/1.73 m\^2 or
* A serum creatinine based on age/gender as follows:
* =\< 0.6 mg/dL (patients age 1 to \< 2 years)
* =\< 0.8 mg/dL (patients age 2 to \< 6 years)
* =\< 1 mg/dL (patients age 6 to \< 10 years)
* =\< 1.2 mg/dL (patients age 10 to \< 13 years)
* =\< 1.4 mg/dL (female patients age \>= 13 years)
* =\< 1.5 mg/dL (male patients age 13 to \< 16 years)
* =\< 1.7 mg/dL (male patients age \>= 16 years)
* Total bilirubin =\< 1.5 x upper limit of normal (ULN) for age
* Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) =\< 3 x ULN = 135 U/L; for the purpose of this study, the ULN for SGPT is 45 U/L
* Serum albumin \>= 2 g/dL
* Serum amylase =\< 1.5 x ULN
* Serum lipase =\< 1.5 x ULN
* Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled
* Patients must be able to swallow tablets whole
* Part C: Archived paraffin-embedded tissue (20 unstained slides or a tumor block) from a prior resection must be available as a control for correlative studies; if tissue blocks or slides are unavailable, the study chair must be notified prior to enrollment
* All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines
* Diagnosis:
* Part A: Patients with recurrent or refractory solid tumors, including lymphoma and CNS tumors, are eligible; patients must have had histologic verification of malignancy at original diagnosis or relapse except in patients with intrinsic brain stem tumors, optic pathway gliomas, or patients with pineal tumors and elevations of cerebrospinal fluid (CSF) or serum tumor markers including alpha-fetoprotein or beta-human chorionic gonadotropin (HCG)
* Part B: Patients with recurrent or refractory high grade glioma (World Health Organization \[WHO\] grade III/IV) including disseminated tumors (excluding diffuse intrinsic pontine glioma \[DIPG\]), not requiring surgical resection; patients must have had histologic verification of malignancy at original diagnosis or relapse
* Part C: Patients with recurrent or refractory high grade glioma (WHO grade III/IV) and requiring surgical resection (excluding DIPG and disseminated tumors), who in the opinion of treating physicians, are medically stable to receive 2 doses of selinexor (8-10 days of treatment) before undergoing surgery without compromising the success of the procedure; note that if, in the opinion of treating physicians, current symptoms necessitate surgery before 2 doses will be able to be received, surgery should not be delayed to administer selinexor, and the patient would be ineligible for protocol therapy
* Disease status:
* Part A: Patients must have either measurable or evaluable disease
* Parts B and C: Patients must have measurable disease on imaging
* Patient's current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life
* Karnofsky \>= 50% for patients \> 16 years of age and Lansky \>= 50 for patients =\< 16 years of age; Note: Neurologic deficits in patients with CNS tumors must have been relatively stable for at least 7 days prior to study enrollment; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
* Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment; if after the required timeframe, the numerical eligibility criteria are met, e.g. blood count criteria, the patient is considered to have recovered adequately
* Myelosuppressive chemotherapy: At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea)
* Hematopoietic growth factors: At least 14 days after the last dose of a long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth factor; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair
* Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair
* Immunotherapy: At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines
* Antibodies: \>= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =\< 1
* Corticosteroids: If used to modify immune adverse events related to prior therapy, \>= 14 days must have elapsed since last dose of corticosteroid
* External beam radiation therapy (XRT): At least 14 days after local palliative XRT (small port); at least 150 days must have elapsed if prior total body irradiation (TBI), craniospinal XRT or if \>= 50% radiation of pelvis; at least 42 days must have elapsed if other substantial bone marrow (BM) radiation
* Stem cell infusion without TBI: No evidence of active graft vs. host disease and at least 56 days must have elapsed after transplant or stem cell infusion
* Patients must not have received prior exposure to selinexor
* For patients with solid tumors without known bone marrow involvement:
* \* Peripheral absolute neutrophil count (ANC) \>= 1000/mm\^3
* \* Platelet count \>= 100,000/mm\^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
* \* Hemoglobin \>= 8.0 g/dL at baseline (may receive red blood cell \[RBC\] transfusions)
* Patients with known bone marrow metastatic disease will be eligible for study if they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity; at least 5 of every cohort of 6 patients must be evaluable for hematologic toxicity for the dose-escalation part of the study; if dose-limiting hematologic toxicity is observed, all subsequent patients enrolled on Part A must be evaluable for hematologic toxicity
* Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70 ml/min/1.73 m\^2 or
* A serum creatinine based on age/gender as follows:
* =\< 0.6 mg/dL (patients age 1 to \< 2 years)
* =\< 0.8 mg/dL (patients age 2 to \< 6 years)
* =\< 1 mg/dL (patients age 6 to \< 10 years)
* =\< 1.2 mg/dL (patients age 10 to \< 13 years)
* =\< 1.4 mg/dL (female patients age \>= 13 years)
* =\< 1.5 mg/dL (male patients age 13 to \< 16 years)
* =\< 1.7 mg/dL (male patients age \>= 16 years)
* Total bilirubin =\< 1.5 x upper limit of normal (ULN) for age
* Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) =\< 3 x ULN = 135 U/L; for the purpose of this study, the ULN for SGPT is 45 U/L
* Serum albumin \>= 2 g/dL
* Serum amylase =\< 1.5 x ULN
* Serum lipase =\< 1.5 x ULN
* Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled
* Patients must be able to swallow tablets whole
* Part C: Archived paraffin-embedded tissue (20 unstained slides or a tumor block) from a prior resection must be available as a control for correlative studies; if tissue blocks or slides are unavailable, the study chair must be notified prior to enrollment
* All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines
Exclusion Criteria
* Pregnant or breast-feeding women will not be entered on this study, since there is yet no available information regarding human fetal or teratogenic toxicities; based on its mechanism of action and findings in animals, selinexor may cause fetal harm when administered to a pregnant woman; pregnancy tests must be obtained in girls who are post-menarchal; males with female partners of reproductive potential or females of reproductive potential may not participate unless they have agreed to use two effective methods of birth control- including a medically accepted barrier method of contraceptive method (e.g., male or female condom) for the entire period in which they are receiving protocol therapy and for at least 1 week following their last dose of study drug; abstinence is an acceptable method of birth control
* Concomitant medications
* Corticosteroids: Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, \>= 14 days must have elapsed since last dose of corticosteroid
* Investigational drugs: Patients who are currently receiving another investigational drug are not eligible
* Anti-cancer agents: Patients who are currently receiving other anti-cancer agents are not eligible
* Patients who have an uncontrolled infection are not eligible
* Patients who have received a prior solid organ transplantation are not eligible
* Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study are not eligible
* Patients with body mass index (BMI) \< 3rd percentile for age, as defined by WHO criteria for patients 1-2 years of age and Centers for Disease Control and Prevention (CDC) criteria for patients \> 2 years of age, are not eligible
* Patients with grade 3 ataxia or grade \>1 extrapyramidal movement disorder are not eligible
* Patients with known macular degeneration, uncontrolled glaucoma, or cataracts are not eligible
* Concomitant medications
* Corticosteroids: Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, \>= 14 days must have elapsed since last dose of corticosteroid
* Investigational drugs: Patients who are currently receiving another investigational drug are not eligible
* Anti-cancer agents: Patients who are currently receiving other anti-cancer agents are not eligible
* Patients who have an uncontrolled infection are not eligible
* Patients who have received a prior solid organ transplantation are not eligible
* Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study are not eligible
* Patients with body mass index (BMI) \< 3rd percentile for age, as defined by WHO criteria for patients 1-2 years of age and Centers for Disease Control and Prevention (CDC) criteria for patients \> 2 years of age, are not eligible
* Patients with grade 3 ataxia or grade \>1 extrapyramidal movement disorder are not eligible
* Patients with known macular degeneration, uncontrolled glaucoma, or cataracts are not eligible
Minimum Eligible Age
12 Months
Maximum Eligible Age
21 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Sponsor Role
collaborator
Children's Oncology Group
NETWORK
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Julia Glade-Bender
Role: PRINCIPAL_INVESTIGATOR
COG Phase I Consortium
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Hospital of Alabama
Birmingham, Alabama, United States
Site Status
Children's Hospital Los Angeles
Los Angeles, California, United States
Site Status
Children's Hospital of Orange County
Orange, California, United States
Site Status
UCSF Medical Center-Mission Bay
San Francisco, California, United States
Site Status
Children's Hospital Colorado
Aurora, Colorado, United States
Site Status
Children's National Medical Center
Washington D.C., District of Columbia, United States
Site Status
Children's Healthcare of Atlanta - Arthur M Blank Hospital
Atlanta, Georgia, United States
Site Status
Lurie Children's Hospital-Chicago
Chicago, Illinois, United States
Site Status
Riley Hospital for Children
Indianapolis, Indiana, United States
Site Status
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Site Status
C S Mott Children's Hospital
Ann Arbor, Michigan, United States
Site Status
University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota, United States
Site Status
Washington University School of Medicine
St Louis, Missouri, United States
Site Status
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, United States
Site Status
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Site Status
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Site Status
Oregon Health and Science University
Portland, Oregon, United States
Site Status
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Site Status
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, United States
Site Status
Saint Jude Children's Research Hospital
Memphis, Tennessee, United States
Site Status
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Houston, Texas, United States
Site Status
Seattle Children's Hospital
Seattle, Washington, United States
Site Status
Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Green AL, Minard CG, Liu X, Safgren SL, Pinkney K, Harris L, Link G, DeSisto J, Voss S, Nelson MD, Reid JM, Fox E, Weigel BJ, Glade Bender J. Phase I Trial of Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors (ADVL1414): A Children's Oncology Group Phase I Consortium Trial. Clin Cancer Res. 2025 May 1;31(9):1587-1595. doi: 10.1158/1078-0432.CCR-24-2754.
Reference Type
DERIVED
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2014-02410
Identifier Type: REGISTRY
Identifier Source: secondary_id
ADVL1414
Identifier Type: -
Identifier Source: secondary_id
ADVL1414
Identifier Type: OTHER
Identifier Source: secondary_id
ADVL1414
Identifier Type: OTHER
Identifier Source: secondary_id
ADVL1414
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
NCT00101270
COMPLETED
PHASE1
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
NCT00015899
COMPLETED
PHASE1
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
NCT00326664
COMPLETED
PHASE1
Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
NCT00047177
COMPLETED
PHASE2
Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors
NCT02015728
UNKNOWN
NA
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
NCT02255461
TERMINATED
PHASE1
Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma
NCT00360945
UNKNOWN
PHASE2
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
NCT03387020
COMPLETED
PHASE1
Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma
NCT00068302
TERMINATED
PHASE1
Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors
NCT03320330
COMPLETED
PHASE1/PHASE2
Study of Vinblastine and Sirolimus in Children With Recurrent/Refractory Solid Tumours Including CNS Tumours
NCT01135563
COMPLETED
PHASE1
Vinorelbine in Treating Children With Recurrent or Refractory Cancers
NCT00003234
COMPLETED
PHASE2
Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors
NCT00281944
COMPLETED
PHASE1
Cilengitide in Treating Children With Refractory Primary Brain Tumors
NCT00063973
COMPLETED
PHASE1
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
NCT01538095
COMPLETED
PHASE1
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
NCT00929903
COMPLETED
PHASE1
Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
NCT04308330
UNKNOWN
PHASE1
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
NCT03690869
TERMINATED
PHASE1/PHASE2
Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma
NCT02163356
TERMINATED
PHASE1
Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors
NCT00107458
COMPLETED
PHASE1
Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma
NCT06620302
RECRUITING
PHASE1/PHASE2
Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
NCT01331135
COMPLETED
PHASE1
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
NCT00100880
COMPLETED
PHASE1
VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors
NCT02164838
COMPLETED
PHASE1
Irinotecan in Treating Children With Refractory Solid Tumors
NCT00004078
COMPLETED
PHASE2